fbpx

Year

2012
Agreement will support future clinical trials of Celladon’s product candidate MYDICAR® for the treatment of advanced heart failure.   Lonza, a global leader in the field of viral therapy manufacturing, and Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that they have entered into...
Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces positive results from its Phase IIa proof-of-concept study investigating APD403 for the prevention of acute nausea & vomiting in cancer patients receiving the highly emetogenic chemotherapy drug cisplatin. Although a number of anti-emetics are available on the market, these...
‘Evolve’ Study Will Assess Safety and Tolerability of Unique Anti-Cancer Agent, ColoAd1   (PsiOxus) has treated the first patient in its phase I/II clinical trial of ColoAd1 for the treatment of metastatic solid tumours. The Evolve (EValuating OncoLytic Vaccine Efficacy) study is the first clinical trial of the systemically available oncolytic vaccine ColoAd1, a highly...
  Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that FierceBiotech named Celladon as one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's tenth annual Fierce 15 selection.   “You don't...
Agreement Covers Distribution Rights of CERAMENT in United States and Canada BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the signing of a multi-year exclusive distribution agreement with Biomet, Inc., a global leader in the manufacture of musculoskeletal medical products. Under...
– 200-Subject Trial of Novel Cell Therapy AC607 at leading tertiary care centers in the United States AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the company’s mesenchymal stem cell therapy, as a potential treatment for acute kidney injury (AKI). The randomized, double-blind, placebo-controlled, multicenter trial, designated ACT-AKI...
Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed the first patient in a Phase 2b clinical trial of MYDICAR, Celladon’s first in class therapeutic for the treatment of advanced heart failure (HF). Chronic HF is a leading cause of hospitalization and...
The Lundbeck Foundation announces the appointment of Mikael Strindlund as a Senior Partner in Lundbeckfond Ventures.
– Patent will further expand intellectual property protection for MYDICAR® – a first in class drug under clinical evaluation for advanced heart failure   Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent...
Investment to Advance ColoAd1 through Phase II Clinical Trial for Colorectal and Other Forms of Cancer PsiOxus Therapeutics, Ltd. (PsiOxus) announced that it has closed a Series B round of equity financing totaling £22 million ($34 million). The round included equal investments from existing investors Imperial Innovations Group (AIM: IVO, ‘Innovations’) and Invesco Perpetual together...
1 2 3 4 5

News

How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020
A 60-year-old’s muscles aren’t old at all
23. March 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge